Reportstack has announced a new market research publication on Investigation Report on China Valsartan Hydrochlorothiazide Market, 2009-2018. According to WHO, one-third of the world's adults have hypertension. The global market value of antihypertensive drugs is tens of billion dollars.
Due to the long history of antihypertensive drugs, most hypertensive patients need 2 or more kinds of antihypertensive drugs to reduce the blood pressure to a normal level. There are more than 20 compound preparations of sartan drugs in global market. The first category is the compound preparation of sartan and diuretic hydrochlorothiazide. Because the compound of sartan drugs and diuretic has better effect than other medication compounds, most sartan and hydrochlorothiazide compound preparations are approved by FDA, including the compound preparation of diuretic chlorthalidone and azilsartan. The second category is the compound preparation of sartan and calcium antagonist. The third category is the direct renin inhibitor and sartan compound preparation. The fourth one is triplex compound preparation. Novartis developed valsartan compound preparation after valsartan was launched. In October 1997, the compound preparation of valsartan hydrochlorothiazide was successfully developed by Novartis and approved by FDA with the trade name "CoDiovan". Unlike valsartan, valsartan hydrochlorothiazide tablet can only treat hypertension instead of congestive heart failure and myocardial infarction.
Statistics shows that the number of hypertensive patients in China is higher than 260 million, which may even be more than 300 million. According to investigation, market value of hypertensive drugs in China exceeds CNY 40 billion every year. The CAGR of sales revenue of valsartan hydrochlorothiazide in Chinese sample hospitals surpassed 100% from 2007 to 2012. Based on the sales revenue, Novartis takes more than 80% of the valsartan hydrochlorothiazide market in China while the other market is seized by Chinese enterprises such as Jiangsu Wangao Pharmaceutical Co., Ltd.
It is estimated that incidence of hypertension in China will continue to rise year by year due to improvement of living standard and changes of lifestyle. As Chinese people's incomes increase, the affordability of antihypertensive drugs increases. As a result, market size of Valsartan Hydrochlorothiazide in China will keep increasing in the next few years.
Through this report, the readers can acquire the following information:
-Market Share of Valsartan Hydrochlorothiazide Produced by Different Enterprises in China Hospital Market
-Sales Value of Valsartan Hydrochlorothiazide in China Hospital Market
-Major Valsartan Hydrochlorothiazide Manufacturers in China
-Prospect of China Valsartan Hydrochlorothiazide Market
The following enterprises and people are recommended to purchase this report:
-Antihypertensive APIs and Finished Product Manufacturers
-Investors /Research Agencies Focusing on China Antihypertensive Drug Market
To view the table of contents and know more details please visit Investigation Report on China Valsartan Hydrochlorothiazide Market, 2009-2018.